Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 6Tumor-Agnostic 5Gastrointestinal 5Lymphoid 4Other hematologic neoplasm 3Thoracic 2Plasma cell 2Head & Neck 2CNS 2Sarcoma 1Other solid neoplasm 1Dermatologic 1

Conditions

Glioma 1Brain Neoplasms 1

Interventions

Temozolomide 610Radiotherapy 388Bevacizumab 254Magnetic Resonance Spectroscopy 203Cyclophosphamide 177Carboplatin 159Radiosurgery 146Etoposide 132Radiation 121Irinotecan 115Vincristine 114Cisplatin 102Filgrastim 100Specimen Handling 88Nivolumab 87pembrolizumab 82Lomustine 81Topotecan 73Surgical Procedures, Operative 73Doxorubicin 60Melphalan 59Carmustine 57sargramostim 53Radiotherapy, Intensity-Modulated 53Isotretinoin 53Peripheral Blood Stem Cell Transplantation 52Granulocyte Colony-Stimulating Factor 50Erlotinib Hydrochloride 50Everolimus 48Chemotherapy, Adjuvant 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Palonosetron × CNS × Clear all
NCT00900757 2019-08-28

Intravenous Palonosetron With Radiotherapy and Concomitant Temozolomide

Duke University

Phase 2 Completed
57 enrolled 10 charts
CNS

Glioma

NCT00636805 2014-04-01

Aloxi for Prevention of Chemotherapy Induced Nausea and Vomiting in Malignant Glioma Patients Receiving Irinotecan With Bevacizumab

Duke University

Phase 2 Terminated
63 enrolled 11 charts
CNS

Brain Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡